Candel Therapeutics, Inc. (CADL) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q3 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Increasing unusual option volume: GPRO JXN ALMS ALLY RSI PCG GTLB OLLI BAM
- Stria Lithium rebrands as Arc Mineral Royalties after gold deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
